NHWD-870

PreclinicalSmall molecule

HHunan Province Tumor Hospital

NHWD-870 is one of 26 small molecule programs targeting Lymphoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

LymphomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Oncaspar

SServier

Preclinical

15 2

Zofran

Novartis

Preclinical

2 3

Norvir

AbbVie

Preclinical

1 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 5

Tafasitamab

Incyte

Preclinical

7 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

PEG-Intron

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphoma1 trial

Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement

Recruiting·HHunan Province Tumor Hospital··NCT06073938·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NHWD-870. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NHWD-870 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NHWD-870. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hunan Province Tumor Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHunan Province Tumor Hospital

NHWD-870

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News